T1	Participants 133 145	in Ethiopia.
T2	Participants 378 446	a large number of human volunteers in India, Vietnam, and Bangladesh
T3	Participants 585 596	in Ethiopia
T4	Participants 607 697	evaluated the safety and immunogenicity of the vaccine in 216 healthy adults and children.
T5	Participants 982 1005	population outside Asia
